Europe Turns to Snowflake Partners for Data Modernization
LONDON--(BUSINESS WIRE)--Enterprises in Europe are rapidly adopting the Snowflake cloud data management platform to support real-time decision-making, accelerate AI adoption and comply with stringent regulations, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.
European enterprises need to overcome the bottlenecks of traditional on-premises data warehouses. Cloud data platforms such as Snowflake provide high performance and efficient support for concurrent users and AI workloads.
The 2025 ISG Provider Lens™ Snowflake Ecosystem Partners report for Europe finds that traditional data platforms are proving inefficient as data volumes surge and enterprises embrace advanced analytics, AI and secure collaboration. As a result, companies in Europe are investing in cloud migration and infrastructure modernization. This change includes the adoption of cloud data platforms that consolidate diverse data types and eliminate silos for improved access and sharing.
'European enterprises need to overcome the scalability and performance bottlenecks of traditional on-premises data warehouses,' said Steve Hall, partner and president, ISG EMEA. 'Cloud data platforms such as Snowflake allow enterprises to scale compute and storage independently, ensuring high performance and efficient support for concurrent users and AI workloads.'
To support large-scale analytics, machine learning (ML) and AI initiatives, European companies are seeking platforms that easily integrate with data science tools, support programming languages such as Python and R and enable in-database ML workflows. Many rely on Snowflake to meet these needs through its tools, accelerators and built-in connectivity with third-party ML platforms. It helps streamline data preparation, model development and deployment so organizations can securely and efficiently implement advanced AI and generative AI (GenAI) solutions, ISG says.
Enterprises in Europe are also focused on transforming data into a strategic asset by sharing it securely across organizations, the report says. Increasingly, they are turning to the Snowflake Marketplace for data monetization projects. As the Snowflake ecosystem matures, service providers are playing a crucial role in helping enterprises unlock the platform's potential, design secure data-sharing architectures and establish data marketplaces.
The report identifies a heightened focus on data governance, compliance and security within the Snowflake ecosystem. As European regulations such as GDPR continue to evolve, enterprises are prioritizing robust data governance frameworks, role-based access controls and continuous monitoring to safeguard sensitive information. IT service providers are helping clients implement these controls, maintain audit-ready environments and achieve regulatory compliance.
'Enterprises migrating to cloud or multicloud environments encounter challenges with data transfer, workload reconfiguration and regulatory compliance,' said Hemangi Patel, senior manager and principal analyst, ISG Provider Lens Research, and lead author of the report. 'Snowflake and its ecosystem partners simplify this transition by allowing companies to implement a fully managed, cloud-agnostic architecture.'
The report also explores other trends in the European Snowflake ecosystem, including the growing importance of partnerships and rising demand for services supporting continuous learning.
For more insights into challenges relevant to the Snowflake ecosystem faced by European enterprises, along with ISG's advice for addressing them, see the ISG Provider Lens™ Focal Points briefing here.
The 2025 ISG Provider Lens™ Snowflake Ecosystem Partners report for Europe evaluates the capabilities of 27 providers across three quadrants: Snowflake Consulting and Advisory Services, Snowflake Implementation Services and Snowflake Managed and Support Services.
The report names Accenture, Capgemini, Cognizant, Deloitte, DXC Technology, Infosys, LTIMindtree and TCS as Leaders in all three quadrants.
In addition, Mphasis is named as a Rising Star — companies with a 'promising portfolio' and 'high future potential' by ISG's definition — in all three quadrants.
The 2025 ISG Provider Lens™ Snowflake Ecosystem Partners report for Europe is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens™ Research
The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Camden National (NASDAQ:CAC) Will Pay A Dividend Of $0.42
The board of Camden National Corporation (NASDAQ:CAC) has announced that it will pay a dividend of $0.42 per share on the 31st of July. This makes the dividend yield 4.1%, which will augment investor returns quite nicely. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. Having distributed dividends for at least 10 years, Camden National has a long history of paying out a part of its earnings to shareholders. Past distributions do not necessarily guarantee future ones, but Camden National's payout ratio of 54% is a good sign as this means that earnings decently cover dividends. The next year is set to see EPS grow by 27.9%. Assuming the dividend continues along recent trends, we think the future payout ratio could be 51% by next year, which is in a pretty sustainable range. Check out our latest analysis for Camden National Even over a long history of paying dividends, the company's distributions have been remarkably stable. The annual payment during the last 10 years was $0.72 in 2015, and the most recent fiscal year payment was $1.68. This works out to be a compound annual growth rate (CAGR) of approximately 8.8% a year over that time. Dividends have grown at a reasonable rate over this period, and without any major cuts in the payment over time, we think this is an attractive combination as it provides a nice boost to shareholder returns. Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Unfortunately things aren't as good as they seem. Over the past five years, it looks as though Camden National's EPS has declined at around 5.4% a year. If earnings continue declining, the company may have to make the difficult choice of reducing the dividend or even stopping it completely - the opposite of dividend growth. Earnings are forecast to grow over the next 12 months and if that happens we could still be a little bit cautious until it becomes a pattern. An additional note is that the company has been raising capital by issuing stock equal to 16% of shares outstanding in the last 12 months. Regularly doing this can be detrimental - it's hard to grow dividends per share when new shares are regularly being created. Overall, we think Camden National is a solid choice as a dividend stock, even though the dividend wasn't raised this year. The earnings coverage is acceptable for now, but with earnings on the decline we would definitely keep an eye on the payout ratio. This looks like it could be a good dividend stock going forward, but we would note that the payout ratio has been at higher levels in the past so it could happen again. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 1 warning sign for Camden National that investors need to be conscious of moving forward. Is Camden National not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Think Costco Wholesale Is Expensive? This Chart Might Change Your Mind.
Costco stock has delivered a 2,320% total return over the past 15 years. The company keeps growing its cash profits while earning increasingly strong returns on its business investments. Costco's ROIC even beats Amazon's in the asset-light e-commerce sector. 10 stocks we like better than Costco Wholesale › Warehouse retailer Costco Wholesale (NASDAQ: COST) may sell goods at affordable prices, but the stock is pretty expensive. Costco investors have pocketed a total return of 2,320% over the last 15 years, leaving the S&P 500 index far behind at a 663% gain. The stock traded at a luxurious 55.8 times trailing earnings on June 26, or 59.6 times free cash flow. So you wouldn't be the first investor to call Costco's stock "expensive." But you might change your mind when you look at the chart below. I'm about to show you a rare combination. Costco has a long-standing habit of growing its cash profits, while also making better and better use of the new capital over time. Free cash flow is the profit that's left over after paying off operating expenses and capital expenses. This capital can be used to finance dividend payouts, execute share buybacks, acquire smaller rivals, or boost the balance sheet's cash reserves. It's a measure of real cash profits, rather than the tax accounting construct you know as net profit or earnings. And Costco earns a lot of cash profits. Return on invested capital (ROIC) measures how effectively a company puts its profits to work. Costco's ROIC is nearly double the figures you see for Walmart (NYSE: WMT) or Target (NYSE: TGT) nowadays, and even exceeds Amazon's (NASDAQ: AMZN) ROIC in the asset-light e-commerce industry. The company also delivers consistently wider ROIC margins over time, while most retailers struggle to keep ROIC stable. As Costco pairs richer ROIC readings with growing cash flows, it keeps feeding a flywheel of constant business improvements. That's an incredibly shareholder-friendly combination. Before you buy stock in Costco Wholesale, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Costco Wholesale wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Anders Bylund has positions in Amazon and Walmart. The Motley Fool has positions in and recommends Amazon, Costco Wholesale, Target, and Walmart. The Motley Fool has a disclosure policy. Think Costco Wholesale Is Expensive? This Chart Might Change Your Mind. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
